Themis Medicare informs about press release

17 Feb 2023 Evaluate
In terms of Regulation 30 of the SEBI (LODR) Regulations, 2015, Themis Medicare has informed that it enclosed a copy of the press release titled - Themis Medicare announces DCGI approval of Remifentanil Hydrochloride 1mg/2mg for injection for import and marketing. 

The above information is a part of company’s filings submitted to BSE.

Themis Medicare Share Price

105.60 -0.70 (-0.66%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×